Company intelligence / Profile preview

Quess

Edmonton, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

The most advanced product candidate is oregovomab, an anti-CA125 monoclonal antibody in combination with front-line chemotherapy for advanced ovarian cancer, currently in a phase IIb clinical trial. The MUC1 program has completed phase I and targets tumor-specific immunization across multiple cancers. A phase I trial is ongoing for the prostate cancer photosensitizer SL052[5].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeVaccineProtein
Industry: Biotech

Partnerships

AD Biotech Co., Ltd.

Beyond the preview

Go deeper on Quess.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quess.

Explore the full profile